Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 3

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  agar diffusion test
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
The genus Scopulariopsis is a common soil saprotroph and has been isolated from air, organic waste and also from plant, animal and human tissues. Scopulariopsis has mainly been associated in humans with superficial mycoses, but it has also been described as the cause of subcutaneous and invasive infections. The most common aetiological agent of infections in humans is Scopulariopsis brevicaulis. This species has been reported to be resistant in vitro to broad-spectrum antifungal agents available today. The aim of the study was to establish in vitro antifungal susceptibility of 35 S. brevicaulis strains against amphotericin B (AMB), flucytosine (FC), caspofungin (CAS), terbinafine (TER), ciclopirox (CIC), voriconazole (VOR), clotrimazole (CTR), miconazole (MCZ), econazole (ECO), ketoconazole (KET), itraconazole (ITR), and fluconazole (FLU). Antifungal susceptibility tests were evaluated by an agar diffusion method (Neo-Sensitabs, Rosco, Denmark). AMB, FC, CAS, ITR and FLU showed no antifungal activity against S. brevicaulis. TER, CIC, CTR, KET, VOR, ECO, and MCZ revealed inhibitory activity for S. brevicaulis, but it varied for each of the drugs. The best antifungal effect was observed for TER and CIC. All isolates had large inhibition zones for TER and CIC. CTR was also inhibitory for all tested S. brevicaulis isolates, but the diameters of inhibition zones were smaller than for TER and CIC. Nearly 89% isolates showed inhibition zones for KET and the mean diameter of the inhibition zone was comparable to CTR. The least antifungal activity exhibited VOR, ECO and MCZ. Because of the multiresistance of S. brevicaulis, infections due to this species may not respond to particular antifungal treatment and other therapeutic approaches should be considered e.g., combined therapy and/or surgery.
The present investigation was evaluating the potential antibacterial activity of three different extracts of the bark of Lannea coromandelica Linn. (LC) tree procured from Eastern India. Extraction of bark separation was carried out using aqueous, ethanol and a mixture of aqueous and ethanol. Microbiocides of all the extracts were separately evaluated against several microorganisms viz. Bacillus substilis, Staphylococcus aureus, Streptococcus pyogenes, Pseudomonus aeruginosa, Escherichia coli and Serratia marcescens by agar diffusion technique. The Minimum Inhibition Concentration (MIC) of all the extracts was carried out by the serial dilution method. The results of MIC ranged from 12.5 to 150 mg/ml (all the three extracts). The concentration dependent (**P < 0.01) potential antimicrobial activity was resulted and at the dose of 200 mg/ml, combined aqueous and ethanol extract of LC (LCAE + LCEE) gave significant results against gram positive bacteria where the maximum zone of inhibition was recorded against Streptococcus pyogenes (17.0± 0.05**) followed by Straphyloccus aureus (13.6 ±0.05**). Further, the same extract showed the maximum relative percentage inhibition against Straphyloccus aureus (178.64%) followed by Streptococcus pyogenes (143.42%). Such variation may be due to the effects of choice of solvent and the quantity of the extracted amount and also the geographical source of the plant part. These results represent scientific evidence to support the traditional medicinal uses of LC bark extracts and indicate a promising potential used against the treatment of infectious diseases caused by pathogenic bacteria and also provide scientific evidence for their efficacy to prepare the alternate newer medicine for antibiotics.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.